Novo announces 25% average weight loss for adult women with next-generation obesity treatment CagriSema
NVO Novo Nordisk ADR
$38.42 -1.06%
View chart & analysis → - 1Novo revealed through a new analysis that CagriSema showed an average weight loss of 25% among adult women.
- 2The weight loss figure for menopausal women in the CagriSema group was 24.8% over 68 weeks if all patients continued the medication.
- 3Analysts expect CagriSema to record $11.804 billion in sales in the obesity sector by 2028.
So what's the key point?
Novo's new obesity treatment reduced the weight of adult women by an average of 25%. Experts expect this drug to reach $11.804 billion in sales by 2028.
Source CNBC +1 · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.